Key statistics
On Monday, Molecular Partners AG (MOLN:SWX) closed at 5.10, 64.25% above the 52 week low of 3.11 set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.95 |
---|---|
High | 5.20 |
Low | 4.91 |
Bid | -- |
Offer | 5.20 |
Previous close | 4.85 |
Average volume | 24.05k |
---|---|
Shares outstanding | 40.36m |
Free float | 35.40m |
P/E (TTM) | -- |
Market cap | 194.05m CHF |
EPS (TTM) | -1.75 CHF |
Data delayed at least 15 minutes, as of Nov 25 2024 16:31 GMT.
More ▼
- Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
- Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
- Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
- Molecular Partners Announces Pricing of $20 Million Underwritten Offering
- Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
- Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
- Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
- Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
- Molecular Partners Reports H1 2024 Corporate Highlights and Financials
- Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
More ▼